
ãææªã®äºæ ã¯ãŸã æ¥ãŠããªãããã¹ãã€ã¯ã¿ã³ãã¯è³ªãå åæ³ç³»ãåŸã ã«å·ã€ããŠãããå°éå®¶ã¯ãã«ã¢ã³é¢é£çŸæ£ã®å¢å ãèŠåããã
ã¯ã¯ãã³ã«å«ãŸããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯å šèº«ã©ããžã§ãäŸµå ¥ããŸããè³å ã§ãå¿èã§ããéãŸãå Žæã«ããããŸãå ç«äœäžãªã©ã«ããããã«äº¡ããªãæ¹ãçç¶ãç¡ãæ¹ãªã©æ§ã ã§ãããå èã¯ãã£ãããã£ããèãŸããŠããããã§ããå»åŠçšèªã¯ãªãã¹ãããããããèšèã«çœ®ãæããŸãããé£ããæããŸãããã©ãããŠãããã¯ã¹ãå¿ èŠãªã®ããçè§£ããŠãã ããðæ¥çš®ããæ¹ã«ãåºããŠãã ããð
ãã©ãžã«ã®å
åæ³åŠè
ã§ãããã©ããªã»ã«ããžã¢ãå士ã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ãã£ãŠèªçºãããå
åæ³ç³»ã®çŸæ£ã¯ããŸã ææªã®ç¶æ
ã«è³ã£ãŠããªãã®ã§ã¯ãªãããšçã£ãŠããŸãã
ãã«ã¢ã³ã¯ãã£ãããšå šèº«ã«äœçšããã®ã§ãå åæ³ç³»ã®æ©èœäžå šãæå·ã¯äžè¬ã«çç¶ã®çºçŸãååŸ©ã«æéãããããšããã©ãžã«ã®å åæ³åŠè ã§ãããã©ããªã»ã«ããžã¢ãå士ã¯èŠåããŠããŸãã
åè:ãšããã¯ã¿ã€ã ãº
https://t.me/covidtruthnet/6044
å åæ³ç³»ã¯ãä¿ã«ãã«ã¢ã³ç³»ãšåŒã°ããç§ãã¡ã®å¥åº·ã«ãšã£ãŠæ¥µããŠéèŠã§ããããã«ã¢ã³ã®åæ³ã«ãã£ãŠãæé·ãçºéãæ°åã代è¬ãçæ®ãå ç«ããã®ä»ã®èåšã®æ©èœã調ç¯ããŠããã®ã§ãã
ãã«ã¢ã³ã¯ãäœå ã®3倧ã¡ãã»ã³ãžã£ãŒã®äžã€ã§ããä»ã®2ã€ã®ã¡ãã»ã³ãžã£ãŒã§ããç¥çµäŒéç©è³ªãšãµã€ãã«ã€ã³ã«æ¯ã¹ããã«ã¢ã³ã¯åå¿ãé ãã屿çãªäœçšã§ã¯ãªããå šèº«çãªæ©èœãæã£ãŠããŸããÂ
COVID-19ææãã¯ã¯ãã³ã«ããã¹ãã€ã¯ã¿ã³ãã¯è³ªããäžåäœãç²ç¶è ºãå¯è ãªã©ã®å åæ³è ºããçæ®åšãªã©ãããŸããŸãªãã®ã«ãã¡ãŒãžãäžããããšãç ç©¶ã§æããã«ãããŠããŸãã
ãã«ã¢ã³ã¯ãã£ãããšå šèº«ã«äœçšããããšãããã®ã§ãå åæ³ç³»ã®æ©èœäžå šãæå·ã¯ãäžè¬ã«çç¶ã®çºçŸãååŸ©ã«æéãããããšèããããŸãã
ã«ããžã¢ãå士ã¯ãå åæ³ç³»ã®ç æ ã¯çºçãé ãããã蚺æãæ²»çã«å°é£ã䌎ãã®ã§ã¯ãªãããšæžå¿µããŠããŸãã
ðððððððððððððð
ãã«ã¢ã³ã®è²¯èµéã®æžå°ð å åæ³è ºã«ã¯ "äºåè» (èã)"ããã
äºåè»ã®æžå°ã¯ä»ããã«ã¯èšåºçã«èŠãããªã
ð
èãããªããªããšçç¶ãçŸãããã
ãã³ãããã¯ãšCOVID-19ã¯ã¯ãã³ã®æäžãå§ãŸã£ãŠä»¥æ¥ãå åæ³ç³»ã®ç æ ã瀺åããå ±åãå¢ããŠããŠãã
ãã«ã¢ã³è»žãšå
šèº«ã®æ©èœé害ð ãã«ã¢ã³ã¯å šèº«ã調ç¯ããŠãã
ãã£ããäºåè»ãæžå°
ð
å åæ³ã®åºç€çŸæ£ãæããã«ãªã
ð
å šèº«ã®èª¿ç¯é害ãåŒãèµ·ããã±ãŒã¹ãããã
âïžå
åæ³è
ºã¯ãå
šèº«ã®å€ãã®èåšã®æ©èœãå¶åŸ¡
ãåå
åæ³èåšã¯ãè»éä¿®æ£ãããŠå¢å¹
ããŠããè
ºã§çµã°ããŠããããããã®è
ºã¯ãã°ãã°å調ããŠäœçšã
ãã®é£éã®é ç¹ãèŠåºäžéš
âïžèŠåºäžéšã¯
â¶äœæž©ã飿¬²ãç¡ç ãäœã®æ°Žåéãå¡©åéã®èª¿æŽèšæ¶ã
â·æèã®èª¿æŽ
Â
äžåäœãšã¯çŽæ¥ã€ãªãã£ãŠããã
äžåäœããåºããã«ã¢ã³ã®èª¿æŽãè¡ãã
âïžäžåäœã¯ãä¿ã«ãã¹ã¿ãŒã°ã©ã³ããšåŒã°ããèŠåºäžéšãšãšãã«ãã«ã¢ã³è»žã圢æããä»ã®å åæ³åšå®ã調ç¯ã
â¶äžåäœã¯èŠåºäžéš-äžåäœ-æ§è
ºïŒHPGïŒè»žã®äžéš
â·åµå·£ã粟巣ãªã©ã®çæ®åšå®ã調ç¯
(女æ§ã§ã¯æçµåšæã®äžéšãšããŠåµå·£ãã«ã¢ã³ã®åæ³ã調ç¯ãã圹å²
ç·æ§ã§ã¯ãã®è»žã粟å圢æã調ç¯)
âïžèŠåºäžéš-äžåäœ-å¯è
ïŒHPAïŒè»ž
éäºã»éèµ°åå¿ãåŒãèµ·ãããã«ã¢ã³ãåæ³ããåšå®ã§ããå¯è
ãåªä»ããç¥çµå
åæ³è»ž
éäºãšéèµ°ã®ããã»ã¹ð
æå®³ãªè
åšã«å¯Ÿå¿ããããã«èµ·ããã¹ãã¬ã¹åå¿
â¶ä»£è¬ãäœäžãâ·å
ç«ãæå¶ãâžäº€æç¥çµç³»ã掻æ§åããã
èŠåºäžéš-äžåäœ-ç²ç¶è ºè»ž
âŽïžç²ç¶è
ºãšãã®åæ³ãããã«ã¢ã³ã調ç¯
ç²ç¶è
ºãã«ã¢ã³ã¯ãæé·ã埪ç°åšç³»ã®èª¿ç¯ã骚ã®çœ®æãèæ©èœã代è¬ãªã©ã®çç©åŠçæ©èœã«äžå¯æ¬ ã§ããã
ã¹ãã€ã¯èçœãå
åæ³ç³»ãã¿ãŒã²ããã«ããä»çµã¿ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãSARS-CoV-2ãŠã€ã«ã¹ã®äžã§æãæ¯æ§ã®é«ãéšå
ç ç©¶ã§ã¯ãæé²ããæ°ã«æããããã¯1幎åŸã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ååšãæ€åºãããããšãå€ãã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãACE2(ãŠã€ã«ã¹ã宿䞻现èã«äŸµå ¥ããå ±ç¯è )ããã³CD147ã¬ã»ãã¿ãŒ(æ©èœçäŸµå ¥ãå©ããçµè·¯)ãäœãåºããŠããçµç¹ãåšå®ãç¹ã«å¥œããèµèãç²ç¶è ºã粟巣ãåµå·£ãå¯è ãäžåäœãªã©å€ãã®å åæ³è ºãACE2å容äœãäœãåºããŠãããå åæ³ç³»ã¯SARS-CoV-2ã«ç¹ã«è匱ã§ããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ããç æ°ã®äž»ãªåå ã¯ãççã§ããã
现èå ã«äŸµå ¥ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯â¶DNAæå·ã®èªçºãâ·DNA修埩ã®é»å®³ãâžçްèã®ãšãã«ã®ãŒç£çã«éèŠãªããã³ã³ããªã¢ãžã®ã¹ãã¬ã¹ð
ççèªçºçµè·¯ã掻æ§åð
ãããã¯ãã¹ãŠã现èã®ã¹ãã¬ã¹ãå·å®³ãçŽ°èæ»ã«ã€ãªããå¯èœæ§ãããã
å€ãã®çްèã圱é¿ãåãããšãçµç¹ãèåšã«åé¡ãåŒãèµ·ãããåã ã®å åæ³è ºãã·ã¹ãã ã«åœ±é¿ãåãŒãã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ã现èã®ããªãµã€ã¯ã«ã·ã¹ãã ãã§ãããªãŒããã¡ãžãŒãé»å®³ããããã现èãæ¯æ§ã¿ã³ãã¯è³ªãæé€ããããšãã§ãããé害ãé·åŒãããšã«ãªãã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãèªå·±å ç«ã«ãé¢äžããŠããå¯èœæ§ð
ããã®äžè¬çãªçµç¹ãã¿ã³ãã¯è³ªãšå€ãã®é¡äŒŒæ§ãæã£ãŠããããããååæš¡å£ããšåŒã°ããå ç«çްèãèªåèªèº«ã®çްèãèåšã«å¯ŸããŠæ»æã仿ããå åæ³é害ã«ã€ãªããå¯èœæ§ãããã
COVID-19ã¯ã¯ãã³æ¥çš®åŸã®å åæ³é害ã«ã€ããŠã¯ãããã€ãã®ç ç©¶ã§å ±åãããŠããããæ£ç¢ºãªé害ã«ã€ããŠã®ããŒã¿ã¯ãŸã åºãŠããŠããªãã
äžåäœå åæ³ç³»ã®ãã¹ã¿ãŒè ºã§ããäžåäœã¯ãä»ã®å åæ³è ºã調ç¯ãããã«ã¢ã³ãã¯ãããå€ãã®ãã«ã¢ã³ãåæ³ããŠããã
â¶å¯è ç®è³ªåºæ¿ãã«ã¢ã³ïŒACTHïŒã¯ãå¯è ãæšçãšããŠãã¹ãã¬ã¹åå¿ãåºæ¿ããã³ã«ããŸãŒã«ãç£çãã圹å²ã
â·ç²ç¶è ºåºæ¿ãã«ã¢ã³ïŒTSHïŒã¯ãç²ç¶è ºã調ç¯ãããã«ã¢ã³ã
âžæé·ãã«ã¢ã³ã¯ãæé·ã代è¬ãåžããã«ã¢ã³ã
â¹ã¡ã©ããµã€ãåºæ¿ãã«ã¢ã³ã¯ã玫å€ç·ã济ã³ããšã¡ã©ãã³ã®çæãä¿é²ãã飿¬²ãå¢é²ãããã
âºæå©å°¿ãã«ã¢ã³ã¯ãæ°Žåãä¿æããå°¿ãå°ãªãããåãã
â»çæ®ã«ã¯é»äœåœ¢æãã«ã¢ã³ïŒLHïŒãåµèåºæ¿ãã«ã¢ã³ïŒFSHïŒãããã©ã¯ãã³ãéèŠã
âŒãªãã·ãã·ã³ã¯ãåºç£ãæ°é³ä»£è¬ãå¹žçŠæãªã©ã«é¢äžã
ð±æ¥æ¬ã§ã¯mRNAã¯ã¯ãã³æ¥çš®åŸã«ACTH(å¯è ç®è³ªåºæ¿ãã«ã¢ã³)æ¬ ä¹çã芳å¯ãããŠããã眹æ£è ã¯äžåäœãçž®å°ããŠããããšã倿ã
ã«ããžã¢ãå士ã«ãããšãäžåäœã®ç çã¯èšºæãé£ãããä»ã®çŸæ£ã«ãã£ãŠé ãããããšãå€ããããCOVID-19ã¯ã¯ãã³æ¥çš®åŸã®äžåäœç ççºçŸã«é¢ããæç®ã¯ã»ãšãã©ãªãã
å¯è
å¯è ã«ãããã¹ãã€ã¯èçœã®å·å®³ã瀺åãã蚌æ ãšããŠäœ¿çšãããå¯èœæ§ã®ããããŒã¿ãæ²èŒãããæç®ããããŸãã
å¯è
ã¯ãè
èã®äžã«äœçœ®ããã¹ãã¬ã¹åå¿ã«é¢äžãããã«ã¢ã³ãç£ç
(ã¢ãã¬ããªã³ãã³ã«ããŸãŒã«ãã¢ã«ãã¹ããã³ãå«ãŸããã)ð
ããã3ã€ã®ãã«ã¢ã³ã®æŸåºã¯ãã¹ãã¬ã¹ã®å€ãç¶æ³äžã§ãšãã«ã®ãŒããã®ä»ã®å¿ èŠãªãã®ãç¶æããããã«éèŠã
COVID-19ã«é¢ããç ç©¶ã§ã¯ãå¯è ãSARS-CoV-2 mRNAã®èç©ãšã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ç£çã®äž»èŠãªéšäœã§ããããšã瀺ãããŠããã
ãã®å¯è
ã¯ãè¥ãç·æ§ã«ããèŠãããã¯ã¯ãã³æ¥çš®åŸã®å¿ççã€ãã³ãã«ãé¢äžããŠããå¯èœæ§ãé«ããã«ããžã¢ãå士ã¯ããã®çš®ã®å¿ççã¯å¯è
æ©èœé害ã®åŸŽåã§ããå¯èœæ§ããããšçç±ãè¿°ã¹ãŠããã
ã«ããžã¢ãå士ã¯ãã¯ã¯ãã³åŸå¿ççã«é¢ããå°éå®¶ã«ããç ç©¶ãå·çããã«ãã³ãŒã«ã¢ãã³/ç¥çµãã«ã¢ã³ã®äžçš®(ããŒããã³ããã«ã¢ãã¬ããªã³ãã¢ãã¬ããªã³ãªã©)ããããã®äºè±¡ã®äž»ãªåŒãéã§ãããšçµè«ã¥ããã
â€ïžâð¥ã¢ãã¬ããªã³ã¯éäºãŸãã¯éèµ°ã®ã¹ãã¬ã¹åå¿ã掻æ§åãããã«ã¢ãã¬ããªã³ã¯å¿ææ°ã®å¢å ãèèªã®åè§£ãè¡ç³å€ã®äžæã«ãã£ãŠãã®åå¿ããµããŒãã
æ¿ããéåãé·æéã®éåã¯éäºã»éèµ°åå¿ãèªçºð
ã¹ããŒãéžæãã«ãã³ãŒã«ã¢ãã³ãé«å€ã§æšç§»ã
ç¹ã«ç·æ§ã¯ã«ãã³ãŒã«ã¢ãã³ã®æ¿åºŠãé«ãåŸåããŸããã¯ã¯ãã³æ¥çš®åŸã«å¿ççã®çºççãé«ããªãã®ããç·æ§ãã«ã¢ã³ã®é¢äžãçãããŠããã
ã¹ãã¬ã¹åå¿ã¯è¡å§ãäžæãããå¿èã®åçž®ã匷ãããæ ¢æ§åãããšå¿çæ¢å¡ã®ãªã¹ã¯ãé«ããå¯èœæ§ãããã
ã«ããžã¢ãå士ã¯ãmRNAã¯ã¯ãã³æ¥çš®ã®3ã4æ¥åŸã«å¿çççŸè±¡ã§æ»äº¡ãã2人ã®10代ã®å°å¹Žã®åæ€å ±åãåæããã«ãã³ãŒã«ã¢ãã³ãšå¿ççãé¢é£ã¥ããã
mRNAãæ¥çš®ããã¢ã¹ãªãŒãã察象ãšããç ç©¶ã§ã¯ãéååŸãæ¥çš®ããäººã¯æ¥çš®ããŠããªãäººã«æ¯ã¹ãŠå¿ææ°ãšãã«ã¢ãã¬ããªã³ã¬ãã«ãé«ããªãããšãããã£ãã
ç²ç¶è
ºç²ç¶è ºã¯ãã®ã©ã®äžã«ããè¶ã®åœ¢ãããè ºã§ããæé·èª¿ç¯ãæ°é³ä»£è¬ãäžå¿ã«ãããŸããŸãªåããããŠããã
ð å ç«ç³»ã®èª¿ç¯ã«é¢äž
COVID-19ã§æ»äº¡ãã15人ã®åæ€èª¿æ»ã«ãããšããã®ãã¡13人ã®ç²ç¶è ºçµç¹ã«ãŠã€ã«ã¹RNAãšã¿ã³ãã¯è³ªãæ€åºãããã
ãŸãããããŸã§ç²ç¶è ºã«ã¯æç€ºãããªããšèããããŠããACE2å容äœãæ€åºãããSARS-CoV-2ã®ææçµè·¯ã®å¯èœæ§ã瀺åããããããã¯ã¯ãã³æ¥çš®è ããããæ€åºãããŠããªãã
äºé²æ¥çš®ã§äœãããã¹ãã€ã¯ç¶ã®ã¿ã³ãã¯è³ªããACE2å容äœã«çµåããŠç²ç¶è ºçްèãæ»æããŠããå¯èœæ§ãããã
èµèèµèã¯ãã°ã«ã«ãŽã³ãšã€ã³ã¹ãªã³ãšããè¡ç³å€ã調ç¯ããéèŠãªãã«ã¢ã³ãç£çãè¡ç³å€ã®ä¹±ãã¯èµèã®æ©èœç°åžžã®è¡šãã§ãããç³å°¿ç ãªã©ã®å䜵çã«ã€ãªããå¯èœæ§ãããã
ã¯ã¯ãã³ããŠã€ã«ã¹ã«å«ãŸããã¹ãã€ã¯ã¿ã³ãã¯ã¯ãç³ä»£è¬ãé»å®³ããå¯èœæ§ãããããšãåãã£ãŠããã
çæ®åšå®COVID-19ã®ç·æ§çæ®åšã«å¯Ÿããæå®³æ§ã¯ååã«ç«èšŒãããŠããã
ã¿ã€ã®ç ç©¶ã§ã¯ãæ§çã«æŽ»çºãªç·æ§153人ã«ãããŠãçŽ64.7%ãCOVID-19ææäžã«åèµ·äžå šãçµéšããå埩åŸ3ã«æçµéããŠã50%ããã®çç¶ãæç¶ããŠããããšã瀺ãããŠããã
åèµ·äžå šã¯å ç®çްèã®æ©èœé害ã«èµ·å ããããšãç ç©¶ã«ãã確ç«ãããŠãããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯å ç®çްèãé害ããã
COVID-19ãšåèµ·äžå šãçµã³ã€ããç ç©¶ã¯ãå ç®çްèã®è¡šé¢ã«è¡šç€ºãããACE2å容äœãšãŠã€ã«ã¹ã®çžäºäœçšãäž»ãªåå ã§ãããšãããŠãããå ç®çްèã«ã¯ACE2å容äœãå€ãååšããCOVID-19ã®ææã§æãæšçãšãªã现èã®äžã€ã§ããã
ð 粟åæäŸã«é¢ããã€ã¹ã©ãšã«ã®ç ç©¶ã§ã¯ãCOVID-19 mRNAã®ã¯ã¯ãã³æ¥çš®ã«ãããç²Ÿåæ¿åºŠã15ïŒ ãéåç²Ÿåæ°ã22ïŒ æžå°ããããšã確èªãããŠããã
â»ãã¹ãããã人ã ã«ã¯åºç€çŸæ£ããªãã£ããããã¯ã¯ãã³æ¥çš®åã«ååšããåºç€çŸæ£ã«ããæžå°ã§ã¯ãªãããšã確èªã
ðµïžå¥³æ§ã§ã¯ãç¹ã«ææåŸãããã¯ã¯ãã³æ¥çš®åŸã«ãçæ®æ©èœã®éå®³ãæžå¿µãããããšãå ±åãããŠããã
ð ã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ïŒVAERSïŒã®ããŒã¿
æå®³äºè±¡å ±åã®60ïŒ
以äžã女æ§ããã§ããã女æ§ãã¯ã¯ãã³æ¥çš®åŸã®çç¶ã«å¯ŸããŠããè匱ã
äžæ±ã®å¥³æ§ã察象ã«ãã調æ»ã§ã¯ã70ïŒ è¿ããã¯ã¯ãã³æ¥çš®åŸã«æçµç°åžžã蚎ããã
åœç«è¡çç ç©¶æãè³éæäŸããç ç©¶â¡ïžCOVID-19ã®ã¯ã¯ãã³æ¥çš®ã«é¢é£ããŠãæçµåšæã®é·ããäžæçã«é·ããªããããšã倿ã
çæ®åšç³»ã®çç¶ã®å€ãã¯ãCOVID-19ã®ææãšã¯é¢ä¿ãªããã¯ã¯ãã³ãšé¢ä¿ãããå¯èœæ§ãããããšã瀺ãããã